South Africa’s Aspen Pharmacare is the latest to throw its weight behind looming off-patent GLP-1 opportunities, disclosing that it has secured a commercial license from an undisclosed company for the intellectual property allowing it to commercialize certain GLP-1s in “early expiry,” non-US and non-EU markets.
In addition, Aspen noted that its agreement would entail the firm being the exclusive global supplier of these products to the licensor – a significant manufacturing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?